Bellevue Life Sciences Acquisition Balance Sheet Health
Financial Health criteria checks 0/6
Bellevue Life Sciences Acquisition has a total shareholder equity of $-4.9M and total debt of $1.6M, which brings its debt-to-equity ratio to -32.5%. Its total assets and total liabilities are $20.6M and $25.5M respectively.
Key information
-32.5%
Debt to equity ratio
US$1.60m
Debt
| Interest coverage ratio | n/a |
| Cash | US$119.12k |
| Equity | -US$4.90m |
| Total liabilities | US$25.54m |
| Total assets | US$20.63m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BLAC.U has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BLAC.U has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BLAC.U has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BLAC.U's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: BLAC.U's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if BLAC.U's interest payments on its debt are well covered by EBIT.